» Articles » PMID: 26912358

Exosome-mediated Transfer of MiR-222 is Sufficient to Increase Tumor Malignancy in Melanoma

Overview
Journal J Transl Med
Publisher Biomed Central
Date 2016 Feb 26
PMID 26912358
Citations 109
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Growing evidence is showing that metastatic cell populations are able to transfer their characteristics to less malignant cells. Exosomes (EXOs) are membrane vesicles of endocytic origin able to convey their cargo of mRNAs, microRNAs (miRs), proteins and lipids from donors to proximal as well as distant acceptor cells. Our previous results indicated that miR-221&222 are key factors for melanoma development and dissemination. The aim of this study was to verify whether the tumorigenic properties associated with miR-222 overexpression can be also propagated by miR-222-containing EXOs.

Methods: EXOs were isolated by UltraCentrifugation or Exoquick-TC(®) methods. Preparations of melanoma-derived vesicles were characterized by using the Nanosight™ technology and the expression of exosome markers analyzed by western blot. The expression levels of endogenous and exosomal miRNAs were examined by real time PCR. Confocal microscopy was used to evaluate transfer and uptake of microvesicles from donor to recipient cells. The functional significance of exosomal miR-222 was estimated by analyzing the vessel-like process formation, as well as cell cycle rates, invasive and chemotactic capabilities.

Results: Besides microvesicle marker characterization, we evidenced that miR-222 exosomal expression mostly reflected its abundance in the cells of origin, correctly paralleled by repression of its target genes, such as p27Kip1, and induction of the PI3K/AKT pathway, thus confirming its functional implication in cancer. The possible differential significance of PI3K/AKT blockade was assessed by using the BKM120 inhibitor in miR-222-transduced cell lines. In addition, in vitro cultures showed that vesicles released by miR-222-overexpressing cells were able to transfer miR-222-dependent malignancy when taken-up by recipient primary melanomas. Results were confirmed by antagomiR-221&222 treatments and by functional observations after internalization of EXOs devoid of these miRs.

Conclusion: All together these data, besides generally confirming the role of miR-222 in melanoma tumorigenesis, supported its responsibility in the exosome-associated melanoma properties, thus further indicating this miR as potential diagnostic and prognostic biomarker and its abrogation as a future therapeutic option.

Citing Articles

The role of exosomal non-coding RNAs in the breast cancer tumor microenvironment.

Saadh M, Allela O, Kareem R, Ballal S, Chahar M, Saini S Funct Integr Genomics. 2025; 25(1):32.

PMID: 39891771 DOI: 10.1007/s10142-025-01531-2.


Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma.

He X, Deng H, Liu W, Hu L, Tan X Curr Treat Options Oncol. 2024; 25(12):1615-1633.

PMID: 39633237 DOI: 10.1007/s11864-024-01279-0.


Therapeutic combinations of exosomes alongside cancer stem cells (CSCs) and of CSC-derived exosomes (CSCEXs) in cancer therapy.

Zabeti Touchaei A, Norollahi S, Najafizadeh A, Babaei K, Bakhshalipour E, Vahidi S Cancer Cell Int. 2024; 24(1):334.

PMID: 39369258 PMC: 11453077. DOI: 10.1186/s12935-024-03514-y.


Extracellular vesicles from highly invasive melanoma subpopulations increase the invasive capacity of less invasive melanoma cells through mir-1246-mediated inhibition of CCNG2.

Kingreen T, Kewitz-Hempel S, Rohde C, Hause G, Sunderkotter C, Gerloff D Cell Commun Signal. 2024; 22(1):442.

PMID: 39285403 PMC: 11403849. DOI: 10.1186/s12964-024-01820-6.


Repressing miR-23a promotes the transdifferentiation of pancreatic α cells to β cells via negatively regulating the expression of SDF-1α.

Lang H, Lin N, Chen X, Xiang J, Zhang X, Kang C PLoS One. 2024; 19(3):e0299821.

PMID: 38517864 PMC: 10959391. DOI: 10.1371/journal.pone.0299821.


References
1.
Tsao H, Chin L, Garraway L, Fisher D . Melanoma: from mutations to medicine. Genes Dev. 2012; 26(11):1131-55. PMC: 3371404. DOI: 10.1101/gad.191999.112. View

2.
Bubka M, Link-Lenczowski P, Janik M, Pochec E, Litynska A . Overexpression of N-acetylglucosaminyltransferases III and V in human melanoma cells. Implications for MCAM N-glycosylation. Biochimie. 2014; 103:37-49. DOI: 10.1016/j.biochi.2014.04.003. View

3.
Felli N, Errico M, Pedini F, Petrini M, Puglisi R, Bellenghi M . AP2α controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression. Oncogene. 2015; 35(23):3016-26. PMC: 4908437. DOI: 10.1038/onc.2015.357. View

4.
Mahabeleshwar G, Byzova T . Angiogenesis in melanoma. Semin Oncol. 2007; 34(6):555-65. PMC: 2365306. DOI: 10.1053/j.seminoncol.2007.09.009. View

5.
Inui M, Martello G, Piccolo S . MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010; 11(4):252-63. DOI: 10.1038/nrm2868. View